Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
FTYZF5tfH5gyuaAf
